United States

USPTO Patent for Respiratory Infection Treatment with Tradipitant

The USPTO has granted a patent to Vanda Pharmaceuticals Inc. for a method of treating lower respiratory tract infections, including those caused by COVID-19 or influenza, using the drug tradipitant. The patent, filed in 2021, details the use of this NK-1 receptor antagonist.

USPTO Grants Patent for Cancer Treatment Pharmaceutical Composition

The USPTO has granted patent US12582638B2 to the Korea Advanced Institute of Science and Technology for a pharmaceutical composition containing an mTOR-signaling inhibitor for treating cancer. The patent, filed on February 19, 2021, claims a composition that inhibits cancer cell growth and has anticancer properties.

USPTO Patent Granted for Proton Pump Inhibitor and Antacid Formulation

The USPTO has granted a new patent (US12582636B2) to HANMI PHARM. CO., LTD. for a pharmaceutical composite formulation containing a proton pump inhibitor and an antacid. This patent covers a specific layered formulation designed for improved drug delivery.

USPTO Patent Granted for Pharmaceutical Agent Delivery Compositions

The USPTO has granted a patent (US12582621B2) for compositions and methods for delivering pharmaceutical agents, specifically hydrogel formulations of suramin for wound healing applications. The patent was assigned to the Arizona Board of Regents on behalf of the University of Arizona.

USPTO Patent Granted for Topical Analgesic Gel Compositions

The USPTO has granted a patent (US12582615B2) to Bayer HealthCare LLC for topical analgesic gel compositions. The patent covers formulations with high payloads of menthol and camphor, utilizing micro-emulsion technology.

USPTO Patent Granted for Lipid Nanoparticle mRNA Delivery

The USPTO has granted a patent (US12582611B2) to ReCode Therapeutics, Inc. for lipid nanoparticle compositions and methods for delivering mRNA encoding the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein to lung cells. The patent focuses on treating or preventing cystic fibrosis.

USPTO Patent Granted for Gastric Residence Dosage Form Coatings

The USPTO has granted a patent (US12582608B2) to Nortiva Bio, Inc. for coatings designed for gastric residence dosage forms. The patent covers formulations comprising water, a plasticizer, a gelling agent, and/or a polymer.

USPTO Patent Granted for Implantable Therapeutic Agent Release Devices

The USPTO has granted patent US12582607B2 to Nano Precision Medical, Inc. for implantable medical devices designed for the extended release of therapeutic agents. The patent covers devices with titanium reservoirs and porous titanium oxide membranes to control drug release rates.

USPTO Patent Grant for Tablet Production Method

The USPTO has granted patent US12582606B2 to SUNSHO PHARMACEUTICAL CO., LTD. for a tablet and a method for producing the tablet. The patent focuses on a technique for stably regulating the amount of an active ingredient without significant cost.

USPTO Patent Granted for Extended Release Cannabinoid Formulations

The USPTO has granted patent US12582605B2 for extended release cannabinoid formulations to Glatt GmbH. The patent covers compositions comprising cannabinoids, drug-releasing agents, surfactants, and a core, potentially including porous beads. This grant is part of the ongoing innovation in pharmaceutical delivery systems for cannabinoids.